# Efficacy and Safety of Peginterferon Alfa-2b and Ribavirin Therapy in Subjects With Type C Compensated Liver Cirrhosis (Study P05116)

> **NCT00687219** · PHASE3 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 102 (actual)

## Conditions studied

- Hepatitis C, Chronic
- Liver Cirrhosis

## Interventions

- **BIOLOGICAL:** Peginterferon alfa-2b
- **DRUG:** Ribavirin

## Key facts

- **NCT ID:** NCT00687219
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-06
- **Primary completion:** 2010-10
- **Final completion:** 2010-10
- **Target enrollment:** 102 (ACTUAL)
- **Last updated:** 2017-04-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00687219

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00687219, "Efficacy and Safety of Peginterferon Alfa-2b and Ribavirin Therapy in Subjects With Type C Compensated Liver Cirrhosis (Study P05116)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00687219. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*